Loading
A phase 2 trial of capecitabine, bevacizumab (glioblastoma use) and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Shanghai Junshi Bioscience Co., Ltd., now recruiting.
JS212 Combination Therapies in Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT07503756 by Shanghai Junshi Bioscience Co., Ltd., with a registry enrolment figure of 80 participants, started 2026-04-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: JS212; Capecitabine; Bevacizumab; Oxaliplatin; JS207. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Investigator-assessed objective response rate (ORR); Safety and Tolerability(AEs); Safety and Tolerability(SAEs). Colorectal eligibility wording from the registry: "* Adults aged 18-75 years with histologically confirmed metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.
Shares Shanghai Junshi Biosciences, FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents and the tag colorectal-deep-dive.
Shares Bevacizumab (glioblastoma use), FOLFOX (5-FU, leucovorin, oxaliplatin), Platinum agents, Colon cancer (adenocarcinoma of the colon) and the tag colorectal-deep-dive.